Equillium (EQ) Announces Katherine Xu, Ph.D. to Board
- Futures muted after S&P 500, Dow hit record closing highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Dollar heads for second week of losses as yields decline
- Morgan Stanley (MS) Tops Q1 EPS by 52c
- Apple (AAPL) May Scrap iPhone Mini Next Year, New Lineup to Focus on Camera Quality, Says Top Analyst
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Equillium, Inc. (NASDAQ: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equillium’s board of directors, effective Thursday, February 4, 2021.
“We’re excited to have Dr. Xu join the board of directors, as she brings with her a wealth of both scientific and Wall Street acumen,” said Dan Bradbury, executive chairman of the board of directors at Equillium. “Her addition complements the skills and experience of our board and her background will add a valuable perspective as Equillium transitions to later-stage development.”
“I’m thrilled to be joining Equillium’s board of directors at such an important time for the company,” said Dr. Xu. “Targeting the CD6-ALCAM pathway to treat severe autoimmune and inflammatory diseases is highly novel and very exciting, as itolizumab recently demonstrated compelling interim data in the first-line treatment of acute graft-versus-host disease. With multiple data milestones on the horizon from all three clinical programs, I look forward to working with the rest of the board and the leadership team as we develop strategies to bring this innovative and impactful therapy to patients with high unmet medical needs.”
Dr. Y. Katherine Xu is a partner at Decheng Capital and has been with the firm since May 2019. Prior to joining Decheng, Dr. Xu was Partner, Senior Biotechnology Analyst and Co-Group Head of the Biopharmaceutical Equity Research team at William Blair & Company based in New York. Prior to William Blair, Dr. Xu was Senior Vice President and Senior Biotechnology Analyst at Wedbush Securities, Vice President and Senior Biotechnology Analyst at Credit Suisse, and Senior Biotechnology Analyst at Pacific Growth Equities. Before her move to equity research, Dr. Xu was Vice President of Investment Banking at Petkevich & Partners, a boutique investment banking firm in San Francisco focused on the life sciences industry. Dr. Xu serves on the board of directors for The 1990 Institute and The Overseas Young Chinese Forum, two China-related non-profit organizations.
Dr. Xu holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively. She attended Peking University in Beijing before transferring to Kalamazoo College in Michigan in her junior year, where she gained her B.A. with honors.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aaron's (AAN) Appoints Laura N. Bailey, Timothy A. Johnson and Marvonia P. Moore to Board
- Bausch Health Co. Inc. (BHC) Reports Brazilian Approval for VYZULTA
- AVEO Oncology (AVEO) Adds Kevin Cullen, M.D. to Board
Create E-mail Alert Related CategoriesBoard Changes, Corporate News, Management Comments
Related EntitiesCredit Suisse, William Blair, Stanford, Pacific Growth Equities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!